PT‑141 (Bremelanotide) is a synthetic melanocortin analog and cyclic heptapeptide that activates central MC4R/MC3R pathways to enhance sexual arousal and desire. Unlike PDE5 inhibitors that increase genital blood flow, it acts centrally within the hypothalamus and limbic system, supporting libido in both men and women. It has been investigated for conditions such as hypoactive sexual desire disorder (HSDD), with clinical studies indicating potential benefits. The peptide is administered via subcutaneous injection and typically reserved for cases unresponsive to first‑line options81314.
Key facts
Also known as: Bremelanotide; cyclic heptapeptide; α‑MSH analog.
Mechanism: selective activation of melanocortin receptors in the brain’s sexual response circuits.
Common presentation: acetate salt; supplied for research or clinical use under medical supervision.
Research scope: female HSDD and male sexual dysfunction; not an aphrodisiac81314.
Safety note This content is for informational purposes only and not a substitute for professional medical advice.
China
